Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Biologics
      • Cancer
      • Cardiology
      • Dermatology
      • Diabetes
      • Hypothyroidism
      • MAC Lung Disease
      • Neurology
      • Primary Care
    • Submit A Question
    close

    Derek LeRoith, MD, PhD

    Derek LeRoith, MD, PhD

    Professor of Medicine
    Director of Research in the Division of Endocrinology, Diabetes and Bone Diseases
    Mount Sinai School of Medicine
    New York, New York


    Related Videos

    Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons? Video

    Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

    Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

    Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA? Video

    Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

    Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

    What is meant exactly by a "fixed ratio" combination? Video

    What is meant exactly by a "fixed ratio" combination?

    What is meant exactly by a “fixed ratio” combination?

    What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira? Video

    What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira?

    What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira?

    How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira? Video

    How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira?

    How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for the safety and efficacy of fixed ratio combinations such as iGlarLixi and iDegLira?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED